DFTX
The table below shows Definium Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$42.63M | -$29.42M | -$16.60M | -$13.33M | -$12.87M | -$10.04M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $42.00M | -$162.46M | $0.00 | - | - | -$316.00K |
| Dividends paid | - | - | - | - | - |
Definium Therapeutics, Inc. reported operating cash flow of -$131.56M for fiscal year 2025. That is down 66.3% from -$79.13M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$23.60M (FY 2020) to -$131.56M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $5.31M | $1.00M | $169.25M | $583.00K | -$166.00K | $89.99M |